| Document |
Document Title |
|
WO/2017/204619A1 |
The present invention provides an aqueous extract of Andrographis paniculata leaves containing as main components andrographolide, neoandrographolide and 14-deoxy-11,12-didehydroandrographolide. The Invention also provides a method of pr...
|
|
WO/2017/197793A1 |
A life-prolonging liquor, consisting of the components of: 10 g of Herba Cistanche, 20 g of Radix Rehmanniae, 10 g of Radix Rehmanniae Preparata, 10 g of Radix Asparagi, 10 g of Radix Ophiopogonis, 20 g of Radix Angelicae Sinensis, 10 g ...
|
|
WO/2017/199073A1 |
An oral pharmaceutical formulation for effervescent tablet of deferiprone is reported comprising of deferiprone and a taste-masking composition consisting of an effective amount of sweetener and flavoring agent and containing appropriate...
|
|
WO/2017/197781A1 |
The present invention provides a health-care and body-strengthening Fructus Lycii liquor, comprising the following components: Fructus Lycii: 50 g; Flos Chrysanthemi: 50 g; Radix Rehmanniae Preparata: 45 g; stir-baked Massa Medicata Ferm...
|
|
WO/2017/195359A1 |
This hop processed product for suppressing fat accumulation or for antioxidation contains greater than or equal to 50 wt%, preferably greater than or equal to 60 wt%, and most preferably greater than or equal to 70%, of hop flowers (E・...
|
|
WO/2017/193458A1 |
Disclosed are an organosilicone modified acrylic polyester potassium salt and a preparation method therefor. The organosilicone modified acrylic polyester potassium salt is prepared from an acrylic acid or esters thereof, acrylic organos...
|
|
WO/2017/192581A1 |
Provided herein are methods for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO c...
|
|
WO/2017/185280A1 |
Disclosed are a biological compound preparation which can improve altitude hypoxia tolerance and a preparation method thereof, comprising the raw materials by weight: 2-10 parts of folium ginkgo extract, 5-15 parts of guarana extract, 10...
|
|
WO/2017/180591A1 |
The invention provides nanozymes that accumulate in the kidney and methods for their use.
|
|
WO/2017/174744A1 |
A delivery system comprising hydrogen peroxide or a hydrogen peroxide generator system, for use in a method for the treatment or prevention of inflammatory bowel disease in a mammal, is described. The method comprises a step of orally ad...
|
|
WO/2017/170762A1 |
The purpose of the present invention is to provide a tablet having sufficient strength and containing spherical adsorptive carbon for oral administration. This purpose is met with a tablet that contains spherical adsorptive carbon for or...
|
|
WO/2017/170764A1 |
The purpose of the present invention is to provide a tablet, and a production method thereof, which has a high absorption rate of spherical adsorptive carbon for oral administration, and a high uniformity of the spherical adsorptive carb...
|
|
WO/2017/169652A1 |
The method for producing polyphenols according to one embodiment of the present invention comprises a step for mixing used tea leaves with water to generate a liquid mixture. The liquid mixture is heated. From the heated liquid mixture, ...
|
|
WO/2017/160864A1 |
The present invention includes a method of protecting or treating neural cells from degeneration comprising: identifying a neural cell in need of protection from at least one of radical oxidative stress, increased mitochondrial biogenesi...
|
|
WO/2017/158041A1 |
The present invention relates to compositions comprising at least one film- forming agent able to adhere in a stable way to the mucosa of the mouth, esophagus and upper airways, establishing a mechanical form of protection against attack...
|
|
WO/2017/159554A1 |
The invention provides a crystal of glutathione having excellent flowability and pulverizability, and a method for producing the same. The invention relates to a crystal of reduced-form glutathione, wherein the average crystal thickness ...
|
|
WO/2017/159555A1 |
The purpose of the invention is to provide: a crystal of reduced-form glutathione in which the content of impurities, particularly L-cysteinyl-L-glycine, is reduced; and a method for producing the same. The invention relates to a crystal...
|
|
WO/2017/157350A1 |
An edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a solubilising age...
|
|
WO/2017/152237A1 |
The present invention relates to new Desferrioxamine B-based compounds that are useful for iron-chelation therapy, to their preparation, and to compositions including the compounds. The present invention also relates to the use of the co...
|
|
WO/2017/152718A1 |
Disclosed are an injection comprising chlorine dioxide for use in the therapeutic goals of promoting the regeneration of stem cells in vivo, and being anti-tumour and anti-ageing, etc., and a preparation method therefor. The injection ha...
|
|
WO/2017/150409A1 |
Provided is a cacao extract with better flavor and in which off-flavor is suppressed, and a method for manufacturing such a cacao extract. The cacao water extract of the present invention contains polyphenol. In this cacao water extract,...
|
|
WO/2017/152114A1 |
A tumescent contravenom solution including: (a) a vasoconstrictor, (b) a physiological crystalloid solution, and (c) optionally a contravenom agent that neutralizes tissue toxic enzymes present in a venom and/or a drug that impairs or pa...
|
|
WO/2017/148183A1 |
Disclosed are a compound traditional Chinese medicine composition containing gynostemma pentaphyllum and a preparation method thereof. The compound traditional Chinese medicine composition containing gynostemma pentaphyllum is made of gy...
|
|
WO/2017/147505A1 |
Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.
|
|
WO/2017/147263A1 |
The present invention relates to an isolated recombinant human lipidated survivin expressed in an Escherichia coli-based system. The isolated recombinant human lipidated survivin augments the expression levels of costimulatory molecules ...
|
|
WO/2017/147522A1 |
The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, and ...
|
|
WO/2017/142961A1 |
The present invention provides a method for treating neurodegenerative disease, traumatic brain injury, or stroke. In particular, the present invention provides a method for using a glycopeptide PACAP/VIP analogues with enhanced CNS pene...
|
|
WO/2017/138626A1 |
A nerve growth promoter and an antioxidant containing a digested product obtained by using a protease to digest a composition containing hyaluronic acid and a protein. A wound treatment agent containing an ethyl acetate extract from a di...
|
|
WO/2017/135286A1 |
Provided are an urolithins-containing aqueous solution comprising urolithins and collagen, a dried solid composition thereof, and a production method therefor, and an urolithins stabilizing method.
|
|
WO/2017/133037A1 |
A health care liquid capable of enhancing human immunity and resisting against ageing comprises, by mass percent, 30% to 60% of original plant juice, 3% to 8% of wine bases, 0 to 15% of auxiliary materials and the balance water. The orig...
|
|
WO/2017/135466A1 |
The present invention relates to a novel composition containing xanthophyll, or a salt thereof, and a processed product of a Trapa genus plant, and to a novel ophthalmic composition containing a processed product of a Trapa genus plant. ...
|
|
WO/2017/129132A1 |
Provided is a healthcare hot compress Chinese medicine bag comprising a Chinese medicine composition and a pharmaceutical bag for packaging the Chinese medicine. The Chinese medicine composition is made from the following components by w...
|
|
WO/2017/130709A1 |
One solid preparation of the present invention has fine silicon particles as a principal component thereof, and exhibits a hydrogen generation capacity. In addition, one embodiment of this solid preparation has fine silicon particles whi...
|
|
WO/2017/131127A1 |
Provided are: a novel bisphosphonic acid compound which exhibits prominent inhibitory activity against ectopic calcification, or a salt thereof; and a pharmaceutical composition containing the compound or salt thereof. The bisphosphonic ...
|
|
WO/2017/125080A1 |
Provided is an application of a fullerene / metal-fullerene micro/nanomaterial for preparing a pharmaceutical product. The pharmaceutical product has at least one of the following properties: 1) treats a bone marrow suppression; 2) treat...
|
|
WO/2015/095553A9 |
The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein...
|
|
WO/2017/125498A1 |
The ratio of the metals zincand cadmium is of great significance for error-free proliferation and differentiation of cells. An understanding of the role of cadmium in the etiology of cancer offers possibilities to gain a better understan...
|
|
WO/2017/126708A1 |
The purpose of the present invention is to provide a prophylactic or therapeutic agent for oxidative stress damages, which is intended to be administered during phacoemulsification and aspiration for cataract. The present invention is a ...
|
|
WO/2017/122120A1 |
Methods, formulations and kits for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent which replenishes, or decreases a loss of, functional glut...
|
|
WO/2017/123823A1 |
This application discloses compounds and pharmaceutical compositions and methods of using the same for inhibition of sulfide:quinone oxidoreductase (SQOR).
|
|
WO/2017/114992A1 |
The invention relates to a method for producing an extract containing hydroxycinnamic acids, characterised in that the method uses one or more vegetable waste products from the production of vegetable food products as a raw material, and...
|
|
WO/2017/115705A1 |
[Problem] To provide a medicinal composition that is capable of improving the prognosis after the restart of the patient's own heartbeat even after the passage of a considerably long period of time after the restart of the patient's own ...
|
|
WO/2017/107628A1 |
The present disclosure belongs to the technical field of pharmaceutical preparations and specifically relates to a chitosan oligosaccharide capsule and method for preparation thereof. The chitosan oligosaccharide capsule comprises conten...
|
|
WO/2017/101793A1 |
The invention belongs to the field of biomedical research involving the 1, 3, 4- selenyldiazo derivatives that have cell protective activity. Because there are not so many heterocyclic selenium compounds, we synthesized a new type of sel...
|
|
WO/2017/103348A1 |
The invention relates to a liquid composition comprising at least one mucosa-lining agent, at least one humectant, and at least one pH adjuster. The invention also relates to the use of said composition as a nasal solution in the prevent...
|
|
WO/2017/104777A1 |
A purpose of the present invention is to provide: a composition for inhibiting carnosine dipeptidase, use of said composition for inhibiting carnosine dipeptidase, and a method for inhibiting carnosine dipeptidase. Another purpose of the...
|
|
WO/2017/100915A1 |
There is provided an improved extraction process for obtaining integral & active thylakoid membranes that have longer shelf-life at room temperature. Particularly, the extract is lyophilized in a solution of PVP and remains stable with a...
|
|
WO/2017/101887A1 |
A healthcare pharmaceutical preparation having magnesium supplementation and anti-oxidation effects, and a preparation method for the healthcare pharmaceutical preparation. The healthcare pharmaceutical preparation comprises a main effec...
|
|
WO/2017/101873A1 |
An application of plasminogen for preventing, treating, improving and/or eliminating radiation and chemical damage and associated diseases in a subject, further providing a novel treatment strategy for treating different types of radiati...
|
|
WO/2017/097182A1 |
The present invention discloses quinoline compounds, a preparation method thereof, and a use thereof as a urate transporter inhibitor drug. The compounds and salts, hydrates or solvates thereof provided in the present invention, as a sel...
|
